One major advance in our understanding of prostate cancer pathogenesis is the recent seminal discovery that more than half of prostate cancers contain a fusion between TMPRSS2, a gene that is highly expressed in the prostate, and the ERG transcription factor. The role of TMPRSS2-ERG fusion in prostate cancer pathogenesis is poorly understood. A crucial limitation to our understanding is the lack of model systems. In this proposal, using three novel genetically-targeted mice, I will attempt to answer the following four questions: 1) where is TMPRSS2 expressed in the prostate and what is the fate of TMPRSS2-expressing cells? 2) what is the phenotype of mice expressing ERG under the TMPRSS2 promoter? 3) within the prostate, which cell types are sensitive to ERG-mediated transformation? and 4) what other genetic events cooperate with TMPRSS2-ERG fusion in carcinogenesis? First, I will generate a mouse expressing an inducible recombination enzyme (tamoxifen-inducible Cre) under the TMPRSS2 promoter, allowing detailed mapping of TMPRSS2 expression patterns and determination of the fate of TMPRSS2-expressing cells in the prostate. This mouse can also be used to activate oncogene/tumor suppressors in TMPRSS2-expressing cells when crossed with previously generated mice that have Cre inducible lesions. Second, I will target the ERG gene into the TMPRSS2 locus. This mouse will be assessed for tumor development, and the prostates will be studied in detail with histology and expression profiling. Third, I wilt target a Cre-inducible ERG into the ubiquitously expressed Rosa26 locus such that ERG will be specifically expressed when crossed with mice harboring tissue-specific Cre that is active in other prostate compartments. Fourth, to find genetic events that cooperate with TMPRSS2-ERG fusion, I will utilize both a candidate approach (crossing with previously generated mouse models harboring genetic lesions found in human prostate cancers) and an unbiased screen approach utilizing transposon mutagenesis that will specifically be activated in TMPRSS2 expressing cells. These studies will offer a comprehensive understanding of the role of TMPRSS2-ERG fusion in prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA140946-04
Application #
8306274
Study Section
Subcommittee G - Education (NCI)
Program Officer
Perkins, Susan N
Project Start
2009-08-11
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
4
Fiscal Year
2012
Total Cost
$159,149
Indirect Cost
$11,789
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Moore, Amanda R; Ceraudo, Emilie; Sher, Jessica J et al. (2016) Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet 48:675-80
Vela, Ian; Chen, Yu (2015) Prostate cancer organoids: a potential new tool for testing drug sensitivity. Expert Rev Anticancer Ther 15:261-3
Ran, Leili; Sirota, Inna; Cao, Zhen et al. (2015) Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discov 5:304-15
Wiesner, Thomas; Lee, William; Obenauf, Anna C et al. (2015) Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature 526:453-7
Gao, Dong; Chen, Yu (2015) Organoid development in cancer genome discovery. Curr Opin Genet Dev 30:42-8
Gao, Dong; Vela, Ian; Sboner, Andrea et al. (2014) Organoid cultures derived from patients with advanced prostate cancer. Cell 159:176-87
Lee, William; Teckie, Sewit; Wiesner, Thomas et al. (2014) PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46:1227-32
Yoshioka, Toshiaki; Otero, Javier; Chen, Yu et al. (2013) β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest 123:682-99
Chen, Yu; Chi, Ping; Rockowitz, Shira et al. (2013) ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 19:1023-9
Clegg, Nicola J; Wongvipat, John; Joseph, James D et al. (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 72:1494-503

Showing the most recent 10 out of 15 publications